N-[tris(hydroxymethyl)methyl]-3-aminopropane | 1177819-85-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-[tris(hydroxymethyl)methyl]-3-aminopropane
• 英文别名: [Tris(hydroxymethyl)methylamino]-propane；2-(hydroxymethyl)-2-(propylamino)propane-1,3-diol
• CAS: 1177819-85-0
• 化学式: C₇H₁₇NO₃
• 分子量: 163.217
• InChiKey: BWVGWYGBCIARRP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.5
• 重原子数：
  11
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  72.7
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  溴丙烷 、 三羟甲基氨基甲烷 以 乙醇 为溶剂， 反应 15.0h， 生成 N-[tris(hydroxymethyl)methyl]-3-aminopropane
  参考文献：
  名称：

  在基于葫芦 [7] 脲的合成主客体系统中揭示了甲铵去溶剂化的焓特征

  摘要：

  Methonium (N(+)Me3) 是一种广泛分布在生物系统中的有机阳离子。作为有机阳离子，甲铵与蛋白质受体的结合需要从水中去除正电荷。甲铵在生物发射器和受体中的出现似乎与报告的四甲基铵 (TMA(+)) 的大量不利去溶剂化自由能不一致，四甲基铵是一种常用的甲铵替代品。在这里，我们报告了一个实验系统，该系统促进了葫芦 [7] 脲 (CB[7]) 分子腔内甲铵的增量内化。结合实验和计算研究，我们表明甲鎓从大量水（部分溶剂化的甲锍状态）转移到 CB[7] 腔（主要是脱溶剂的甲锍状态）伴随着非常小的脱溶剂焓，仅为 0。5 ± 0.3 kcal·mol(-1)，吸热值明显低于气相模型研究建议的值。我们的结果与中子散射测量结果一致，这表明甲鎓在大量水结构中仅产生最小的扰动，这突出了气相模型的局限性。更令人惊讶的是，甲铵表面从水中逐渐撤出会在去溶剂化焓中产生非单调响应。存在部分去溶剂化状态，其中一

  DOI：

  10.1021/ja311327v

文献信息

• [EN] NOVEL SYNTHETIC ANALOGS OF SPHINGOLIPIDS<br/>[FR] NOUVEAUX ANALOGUES SYNTHÉTIQUES DE SPHINGOLIPIDES
  申请人：YISSUM RES DEV CO

  公开号：WO2009060457A1

  公开（公告）日：2009-05-14

  The present invention provides new ceramide analogs indicated as the compounds of formula (II). These novel analogs exhibit a significant anti cancerous effect and are therefore provided as a pharmaceutical composition for treating cell proliferative diseases, neurodegenerative disorders, metabolism-associated conditions, infectious diseases, and immune-related disorders. The invention further provides combined compositions and kits combining the novel ceramide analogs of formula (II) with an additional therapeutic agent.

  本发明提供了新的鞘氨醇类似物，表示为式（II）的化合物。这些新颖的类似物表现出显著的抗癌效果，因此被作为治疗细胞增殖性疾病、神经退行性疾病、与代谢相关的疾病、传染病和免疫相关疾病的药物组合物。该发明还提供了将式（II）的新颖鞘氨醇类似物与额外治疗剂结合的联合组合物和配套工具。
• NOVEL SYNTHETIC ANALOGS OF SPHINGOLIPIDS
  申请人：Dagan Arie

  公开号：US20110034542A1

  公开（公告）日：2011-02-10

  The present invention provides new ceramide analogs indicated as the compounds of formula (II). These novel analogs exhibit a significant anti cancerous effect and are therefore provided as a pharmaceutical composition for treating cell proliferative diseases, neurodegenerative disorders, metabolism-associated conditions, infectious diseases, and immune-related disorders. The invention further provides combined compositions and kits combining the novel ceramide analogs of formula (II) with an additional therapeutic agent.

  本发明提供了新的神经酰胺类似物，其被表示为式（II）的化合物。这些新型类似物表现出显著的抗癌作用，因此提供了作为治疗细胞增殖性疾病、神经退行性疾病、代谢相关疾病、传染病和免疫相关疾病的药物组合物。本发明还提供了将式（II）的新型神经酰胺类似物与其他治疗剂组合的组合物和工具包。
• Wettable surface modified contact lens fabricated from an oxirane containing hydrophobic polymer
  申请人：CIBA-GEIGY AG

  公开号：EP0276631A1

  公开（公告）日：1988-08-03

  A contact lens possessing a wettable surface in its ocular aqueous environment of use fabricated from a hydrophobic addition polymer incorporating between about 0.5 and about 30 % by weight oxirane substituted units in the backbone thereof, wherein the outer surfaces of said lens contain an effective hydrophilicity inducing amount of a reaction product of said oxirane substituted units of the formula I, wherein R is hydrogen or methyl; R¹ is carbonyl or lower alkylene; n is 1 to 4; and R⁰ is hydrogen or with a reactive water soluble nucleopile selected from an organic amine, alcohol, thiol, urea or thiourea, or sulfite, bisulfite or thio­sulfate and the use thereof by placement in the eye of a patient in need of the same to correct vision defects of a refractive nature.

  一种隐形眼镜，其在使用时的眼部水环境中具有可润湿表面，该隐形眼镜由疏水加成聚合物制成，在其骨架中含有约 0.5%至约 30%（按重量计）的环氧乙烷取代单元，其中所述镜片的外表面含有有效亲水性诱导量的式 I 所述环氧乙烷取代单元的反应产物、 其中 R 是氢或甲基；R¹ 是羰基或低级亚烷基；n 是 1 至 4；以及 R⁰ 是氢或 与选自有机胺、醇、硫醇、脲或硫脲，或亚硫酸盐、亚硫酸氢盐或硫代硫酸盐的活性水溶性核载体的反应产物，并将其置于有需要的患者眼中，以矫正屈光性质的视力缺陷。
• A composition for the treatment of exocrine insufficiency of the pancreas, and the use of said composition
  申请人：Scharpé, Simon Lodewijk

  公开号：EP0387945A1

  公开（公告）日：1990-09-19

  The invention relates to a composition for the treatment of exocrine insufficiency of the pancreas, comprising as active components a microbial lipase and a mammalian pancreatic extract, and a pharmaceutically acceptable carrier or diluent, preferably the microbial lipase is upgraded to a specific activity of more than 125,000, preferably 600,000, more preferably 1,500,000 FIP U/g.

  本发明涉及一种治疗胰腺外分泌功能不全的组合物，其活性成分包括微生物脂肪酶和哺乳动物胰腺提取物，以及药学上可接受的载体或稀释剂，其中微生物脂肪酶的比活性最好提高到 125,000 U/g以上，最好是600,000 U/g，更理想的是1,500,000 FIP U/g。
• Polypeptide and process for measuring living body components using the same
  申请人：WAKO PURE CHEMICAL INDUSTRIES, LTD

  公开号：EP1273591A1

  公开（公告）日：2003-01-08

  A process is provided for measuring an analyte in a sample derived from a living body which comprises: reacting a sample derived from a living body with a reagent, which reagent comprises a combined product of a polypeptide having 3 to 30 acid residues derived from a strong acid and a substance having affinity for the analyte, separating the resulting complex, and determining the amount of the analyte in the sample on the basis of the amount of the complex. A polypeptide is provided which may be represented by the formula:         A―(R1)m'―B     [II] wherein R1's are, the same or different, independently an amino acid residue introducing a strong acid residue derived from a strong acid having a pKa of 3 or lower thereinto by binding to a reactive group of the amino acid residue, said reactive group being selected from a hydroxyl group, an amino group, an imino group and a thiol group; m' is an integer of 3 to 30; A is a hydrogen atom, a protective group of N-terminus or an acid residue derived from the strong acid; and B is a hydroxyl group or a protective group of C-terminus; excluding those polypeptides having 3 to 20 tyrosine sulfate residues.

  提供了一种用于测量来自活体的样品中的分析物的方法，该方法包括：将来自活体的样品与一种试剂反应，该试剂包括具有 3 至 30 个酸残基的强酸多肽与一种对分析物具有亲和力的物质的结合产物；分离所产生的复合物；根据复合物的量确定样品中分析物的量。 本发明提供了一种可由式表示的多肽： A-(R1)m'-B[Ⅱ] 其中 R1's 相同或不同，独立地为氨基酸残基，通过与氨基酸残基的反应基团结合，引入由其中 pKa 为 3 或更低的强酸衍生的强酸残基，所述反应基团选自羟基、氨基、亚氨基和硫醇基团；m'是 3 至 30 的整数；A 是氢原子、N-末端的保护基团或由强酸衍生的酸残基；B 是羟基或 C-末端的保护基团；不包括具有 3 至 20 个硫酸酪氨酸残基的多肽。